Effectiveness and Response Predictors of Omalizumab in Treating Patients with Seasonal Allergic Rhinitis: A Real-World Study

References

• Khan David A. Allergic rhinitis and asthma: epidemiology and common pathophysiology. Allergy Asthma Proc. 2014;35(5):357–361. doi:10.2500/aap.2014.35.3794
   Web of Science ®Google Scholar
• Testa D, DI Bari M, Nunziata M, et al. Allergic rhinitis and asthma assessment of risk factors in pediatric patients: A systematic review. Int J Pediatr Otorhinolaryngol. 2020;129:109759. doi:10.1016/j.ijporl.2019.109759
   PubMed Web of Science ®Google Scholar
• Wang XD, Zheng M, Lou HF, et al. An increased prevalence of self-reported allergic rhinitis in major Chinese cities from 2005 to 2011. Allergy. 2016;71(8):1170–1180. doi:10.1111/all.12874
   PubMed Web of Science ®Google Scholar
• Wang X-Y, Ma -T-T, Wang X-Y, et al. Prevalence of pollen-induced allergic rhinitis with high pollen exposure in grasslands of Northern China. Allergy. 2018;73(6):1232–1243. doi:10.1111/all.13388
   PubMed Web of Science ®Google Scholar
• Kulig M, Klettke U, Wahn V, Forster J, Bauer C-P, Wahn U. Development of seasonal allergic rhinitis during the first 7 years of life. J Allergy Clin Immunol. 2000;106(5):832–839. doi:10.1067/mai.2000.110098
   PubMed Web of Science ®Google Scholar
• Pastacaldi C, Lewis P, Howarth P. Staphylococci and staphylococcal superantigens in asthma and rhinitis: a systematic review and meta-analysis. Allergy. 2011;66(4):549–555. doi:10.1111/j.1398-9995.2010.02502.x
   Web of Science ®Google Scholar
• Valero A, et al. Development and validation of a new Spanish instrument to measure health-related quality of life in patients with allergic rhinitis: the ESPRINT Questionnaire. Value Health. 2007;10(6):466–477. doi:10.1111/j.1524-4733.2007.00202.x
   Web of Science ®Google Scholar
• Colás C, Brosa M, Antón E, et al. Estimate of the total costs of allergic rhinitis in specialized care based on real-world data: the FERIN Study. Allergy. 2017;72(6):959–966. doi:10.1111/all.13099
   PubMed Web of Science ®Google Scholar
• Johnston NW. Asthma exacerbations {middle dot} 1: epidemiology. Thorax. 2006;61(8):722–728. doi:10.1136/thx.2005.045161
   PubMed Web of Science ®Google Scholar
• Bousquet J, Schünemann HJ, Samolinski B, et al. Allergic rhinitis and its impact on asthma (ARIA): achievements in 10 years and future needs. J Allergy Clin Immunol. 2012;130(5):1049–1062. doi:10.1016/j.jaci.2012.07.053
   PubMed Web of Science ®Google Scholar
• Wallace DV, Dykewicz MS, Bernstein DI, et al. The diagnosis and management of rhinitis: an updated practice parameter. J Allergy Clin Immunol. 2008;122(2):S1–S84. doi:10.1016/j.jaci.2008.06.003
   PubMed Web of Science ®Google Scholar
• Juel-Berg N, Darling P, Bolvig J, et al. Intranasal corticosteroids compared with oral antihistamines in allergic rhinitis: A systematic review and meta-analysis. Am J Rhinol Allergy. 2017;31(1):19–28. doi:10.2500/ajra.2016.30.4397
   PubMed Web of Science ®Google Scholar
• Meltzer EO. Pharmacotherapeutic strategies for allergic rhinitis: matching treatment to symptoms, disease progression, and associated conditions. Allergy Asthma Proc. 2013;34(4):301–311. doi:10.2500/aap.2013.34.3676
   Web of Science ®Google Scholar
• Wei C. The efficacy and safety of H1-antihistamine versus Montelukast for allergic rhinitis: A systematic review and meta-analysis. Biomed Pharmacother. 2016;83:989–997. doi:10.1016/j.biopha.2016.08.003
   Web of Science ®Google Scholar
• Nyborg AC, Zacco A, Ettinger R, et al. Development of an antibody that neutralizes soluble IgE and eliminates IgE expressing B cells. Cell Mol Immunol. 2016;13(3):391–400. doi:10.1038/cmi.2015.19
   Web of Science ®Google Scholar
• Casale TB, Condemi J, Laforce C, et al. Effect of omalizumab on symptoms of seasonal allergic rhinitis: a randomized controlled trial. JAMA. 2001;19:2956–2967. doi:10.1001/jama.286.23.2956
   Web of Science ®Google Scholar
• Kuehr J, Brauburger J, Zielen S, et al. Efficacy of combination treatment with anti-IgE plus specific immunotherapy in polysensitized children and adolescents with seasonal allergic rhinitis. J Allergy Clin Immunol. 2002;109(2):274–280. doi:10.1067/mai.2002.121949
   PubMed Web of Science ®Google Scholar
• Okubo K, Ogino S, Nagakura T, Ishikawa T. Omalizumab is effective and safe in the treatment of Japanese cedar pollen-induced seasonal allergic rhinitis. Allergol Int. 2006;55(4):379–386. doi:10.2332/allergolint.55.379
   PubMedGoogle Scholar
• Cavaliere C, Begvarfaj E, Incorvaia C, et al. Long-term omalizumab efficacy in allergic rhinitis. Immunol Lett. 2020;227:81–87. doi:10.1016/j.imlet.2020.08.002
   PubMed Web of Science ®Google Scholar
• Okubo K, Okano M, Sato N, et al. Add-on omalizumab for inadequately controlled severe pollinosis despite standard-of-care: a randomized study. J Allergy Clin Immunol Pract. 2020;8(3130):3130–3140.e2. doi:10.1016/j.jaip.2020.04.068
   Web of Science ®Google Scholar
• Juniper EF, Guyatt GH. Development and testing of a new measure of health status for clinical trials in rhinoconjunctivitis. Clin Exp Allergy. 1991;21(1):77–83. doi:10.1111/j.1365-2222.1991.tb00807.x
   PubMed Web of Science ®Google Scholar
• Humbert M, Boulet LP, Niven RM, Panahloo Z, Blogg M, Ayre G. Omalizumab therapy: patients who achieve greatest benefit for their asthma experience greatest benefit for rhinitis. Allergy. 2009;64(1):81–84. doi:10.1111/j.1398-9995.2008.01846.x
   PubMed Web of Science ®Google Scholar
• Kowalski ML, Ansotegui I, Aberer W, et al. Risk and safety requirements for diagnostic and therapeutic procedures in allergology: world Allergy Organization Statement. World Allergy Organ J. 2016;9:33. doi:10.1186/s40413-016-0122-3
   PubMed Web of Science ®Google Scholar
• Licari A, Marseglia G, Castagnoli R, Marseglia A, Ciprandi G. The discovery and development of omalizumab for the treatment of asthma. Expert Opin Drug Discov. 2015;10(9):1033–1042. doi:10.1517/17460441.2015.1048220
   PubMed Web of Science ®Google Scholar
• Bousquet J, Cabrera P, Berkman N, et al. The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma. Allergy. 2005;60(3):302–308. doi:10.1111/j.1398-9995.2004.00770.x
   PubMed Web of Science ®Google Scholar
• Busse WW, Morgan WJ, Gergen PJ, et al. Randomized trial of omalizumab (anti-IgE) for asthma in inner-city children. N Engl J Med. 2011;364(11):1005–1015. doi:10.1056/NEJMoa1009705
   PubMed Web of Science ®Google Scholar
• Li J, Kang J, Wang C, et al. Omalizumab improves quality of life and asthma control in Chinese patients with moderate to severe asthma: A randomized phase III study. Allergy Asthma Immunol Res. 2016;8(4):319–328. doi:10.4168/aair.2016.8.4.319
   PubMed Web of Science ®Google Scholar
• Wang HH, Li YC, Huang YC. Efficacy of omalizumab in patients with atopic dermatitis: A systematic review and meta-analysis. J Allergy Clin Immunol. 2016;138:1719–1722. doi:10.1016/j.jaci.2016.05.038
   PubMed Web of Science ®Google Scholar
• Tsabouri S, Tseretopoulou X, Priftis K, Ntzani EE. Omalizumab for the treatment of inadequately controlled allergic rhinitis: a systematic review and meta-analysis of randomized clinical trials. J Allergy Clin Immonol Pract. 2014;2:332–340. doi:10.1016/j.jaip.2014.02.001
   PubMed Web of Science ®Google Scholar
• Kamin W, Kopp MV, Erdnuess F, Schauer U, Zielen S, Wahn U. Safety of anti-IgE treatment with omalizumab in children with seasonal allergic rhinitis undergoing specific immunotherapy simultaneously. Pediatr Allergy Immunol. 2010;21(1–Part–II):e160–e165. doi:10.1111/j.1399-3038.2009.00900.x
   Web of Science ®Google Scholar
• Klunker S, Saggar LR, Seyfert-Margolis V, et al. Combination treatment with omalizumab and rush immunotherapy for ragweed-induced allergic rhinitis: inhibition of IgE-facilitated allergen binding. J Allergy Clin Immunol. 2007;120(3):688–695. doi:10.1016/j.jaci.2007.05.034
   PubMed Web of Science ®Google Scholar
• Kopp MV, Hamelmann E, Zielen S, et al. Combination of omalizumab and specific immunotherapy is superior to immunotherapy in patients with seasonal allergic rhinoconjunctivitis and co-morbid seasonal allergic asthma. Clin Exp Allergy. 2009;39(2):271–279. doi:10.1111/j.1365-2222.2008.03121.x
   PubMed Web of Science ®Google Scholar
• Togias A. Rhinitis and asthma: evidence for respiratory system integration. J Allergy Clin Immunol. 2003;111(6):1171–1183. doi:10.1067/mai.2003.1592
   PubMed Web of Science ®Google Scholar
• Price D, Zhang Q, Kocevar VS, Yin DD, Thomas M. Effect of a concomitant diagnosis of allergic rhinitis on asthma-related health care use by adults. Clin Exp Allergy. 2005;35(3):282–287. doi:10.1111/j.1365-2222.2005.02182.x
   PubMed Web of Science ®Google Scholar
• Bousquet J, Gaugris S, Kocevar VS, et al. Increased risk of asthma attacks and emergency visits among asthma patients with allergic rhinitis: a subgroup analysis of the improving asthma control trial. Clin Exp Allergy. 2005;35(6):723–727. doi:10.1111/j.1365-2222.2005.02251.x
   PubMed Web of Science ®Google Scholar
• Gibson PG, Reddel H, McDonald VM, et al. Effectiveness and response predictors of omalizumab in a severe allergic asthma population with a high prevalence of comorbidities: the Australian Xolair Registry. Int Med J. 2016;46(9):1054–1062. doi:10.1111/imj.13166
   Google Scholar
• Shi Z, Xu M, Chen X, Wang J, Zhao T, Zha D. The regulatory role of SFRP5/WNT5A axis in allergic rhinitis through inhibiting JNK pathway activation and lowering mucin generation in human nasal epithelial cells.. Exp Mol Pathol. 2020;118:104591. doi:10.1016/j.yexmp.2020.104591
   Web of Science ®Google Scholar
• Fahy J. Type 2 inflammation in asthma — present in most, absent in many. Nat Rev Immunol. 2015;15(1):57–65. doi:10.1038/nri3786
   PubMed Web of Science ®Google Scholar
• Dunican E, Fahy J. The Role of Type 2 Inflammation in the Pathogenesis of Asthma Exacerbations.. Ann Am Thorac Soc. 2015;12 Suppl 2(Suppl 2):S144. doi:10.1513/AnnalsATS.201506-377AW
   Web of Science ®Google Scholar
• Riccio A, Tosca M, Cosentino C, et al. Cytokine pattern in allergic and non-allergic chronic rhinosinusitis in asthmatic children. Clin Exp Allergy. 2002;32(3):422–426. doi:10.1046/j.1365-2222.2002.01315.x
   Web of Science ®Google Scholar
• Manka L, Wechsler M. New biologics for allergic diseases. Expert Rev Clin Immunol. 2018;14(4):285–296. doi:10.1080/1744666X.2018.1459188
   PubMed Web of Science ®Google Scholar
• Hanania N, Wenzel S, Rosen K, et al. Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study. Am J Respir Crit Care Med. 2013;187(8):804–811. doi:10.1164/rccm.201208-1414OC
   PubMed Web of Science ®Google Scholar